Arginine-vasopressin receptor blocker conivaptan reduces brain edema and blood-brain barrier disruption after experimental stroke in mice

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  Zeynalov, Emil ^a   Jones, Susan M ^a   Seo, Jeong Woo ^a   Snell, Lawrence D ^b   Elliott, J Paul ^c   Ahmad, Muzamil ^d  

^a SWEDISH MEDICAL CENTER   (United States)

^b Colorado Neurological Institute ^*  (United States)

^c Department of Neurosurgery   (United States)

^d CSIR INDIAN INSTITUTE OF INTEGRATIVE MEDICINE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CONIVAPTAN; EVANS BLUE; SODIUM; TOLVAPTAN; VASOPRESSIN RECEPTOR ANTAGONIST; BENZAZEPINE DERIVATIVE; VASOPRESSIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN EDEMA; BRAIN ISCHEMIA; BRAIN WATER; CONTINUOUS INFUSION; CONTRAST MEDIUM EXTRAVASATION; CONTROLLED STUDY; EXPERIMENTAL STROKE; LOADING DRUG DOSE; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NEUROLOGIC DISEASE; NONHUMAN; PLASMA OSMOLALITY; SODIUM BLOOD LEVEL; SODIUM URINE LEVEL; URINE OSMOLALITY; ANIMAL; DISEASE MODEL; DRUG EFFECTS; ELECTROLYTE BALANCE; METABOLISM; PATHOLOGY; STROKE;

ANIMALS; ANTIDIURETIC HORMONE RECEPTOR ANTAGONISTS; BENZAZEPINES; BLOOD-BRAIN BARRIER; BRAIN EDEMA; DISEASE MODELS, ANIMAL; MICE; RECEPTORS, VASOPRESSIN; STROKE; WATER-ELECTROLYTE BALANCE;

EID: 84943154453     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0136121     Document Type: Article

References (41)

1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. Heart disease and stroke statistics-2014 update: a report from the american heart association. Circulation. 2014; 129(3):e28-e292. doi:10.1161/01.cir.0000441139.02102.80 PMID: 24352519.
2. Westermaier T, Stetter C, Raslan F, Vince GH, Ernestus RI. Brain edema formation correlates with perfusion deficit during the first six hours after experimental subarachnoid hemorrhage in rats. Experimental & translational stroke medicine. 2012; 4(1):8. doi:10.1186/2040-7378-4-8 PMID: 22551223; PubMed Central PMCID: PMC3398845.
3. Baylis PH. The syndrome of inappropriate antidiuretic hormone secretion. The international journal of biochemistry & cell biology. 2003; 35(11):1495-9. PMID: 12824060.
4. Barreca T, Gandolfo C, Corsini G, Del Sette M, Cataldi A, Rolandi E, et al. Evaluation of the secretory pattern of plasma arginine vasopressin in stroke patients. Cerebrovasc Dis. 2001; 11(2):113-8. PMID: 11223663.
5. Vantyghem MC, Balavoine AS, Wemeau JL, Douillard C. Hyponatremia and antidiuresis syndrome. Annales d'endocrinologie. 2011; 72(6):500-12. doi:10.1016/j.ando.2011.10.001 PMID: 22119069.
6. Weber R, Pechere-Bertschi A, Hayoz D, Gerc V, Brouard R, Lahmy JP, et al. Effects of SR 49059, a new orally active and specific vasopressin V1 receptor antagonist, on vasopressin-induced vasoconstriction in humans. Hypertension. 1997; 30(5):1121-7. PMID: 9369265.
7. Wun T, Paglieroni T, Lachant NA. Physiologic concentrations of arginine vasopressin activate human platelets in vitro. British journal of haematology. 1996; 92(4):968-72. PMID: 8616095.
8. Coussement J, Danguy C, Zouaoui-Boudjeltia K, Defrance P, Bankir L, Biston P, et al. Treatment of the syndrome of inappropriate secretion of antidiuretic hormone with urea in critically ill patients. American journal of nephrology. 2012; 35(3):265-70. doi:10.1159/000336716 PMID: 22378162.
9. Nase G, Helm PJ, Enger R, Ottersen OP. Water entry into astrocytes during brain edema formation. Glia. 2008; 56(8):895-902. doi:10.1002/glia.20664 PMID: 18351631.
10. D'Auria D, Marinosci GZ, De Benedictis G, Piazza O. Vaptans and hyponatremia in critical patients. Translational medicine @ UniSa. 2012; 3:1-14. PMID: 23905047; PubMed Central PMCID: PMC3728787.
11. Liu X, Nakayama S, Amiry-Moghaddam M, Ottersen OP, Bhardwaj A. Arginine-vasopressin V1 but not V2 receptor antagonism modulates infarct volume, brain water content, and aquaporin-4 expression following experimental stroke. Neurocritical care. 2010; 12(1):124-31. doi:10.1007/s12028-009-9277-x PMID: 19806476.
12. Kleindienst A, Dunbar JG, Glisson R, Marmarou A. The role of vasopressin V1A receptors in cytotoxic brain edema formation following brain injury. Acta Neurochir (Wien). 2013; 155(1):151-64. doi:10.1007/s00701-012-1558-z PMID: 23188468.
13. Kleindienst A, Fazzina G, Dunbar JG, Glisson R, Marmarou A. Protective effect of the V1a receptor antagonist SR49059 on brain edema formation following middle cerebral artery occlusion in the rat. Acta neurochirurgica Supplement. 2006; 96:303-6. PMID: 16671476.
14. Manaenko A, Fathali N, Khatibi NH, Lekic T, Hasegawa Y, Martin R, et al. Arginine-vasopressin V1a receptor inhibition improves neurologic outcomes following an intracerebral hemorrhagic brain injury. Neurochem Int. 2011; 58(4):542-8. doi:10.1016/j.neuint.2011.01.018 PMID: 21256175; PubMed Central PMCID: PMC3063401.
15. Manaenko A, Fathali N, Khatibi NH, Lekic T, Shum KJ, Martin R, et al. Post-treatment with SR49059 improves outcomes following an intracerebral hemorrhagic stroke in mice. Acta neurochirurgica. 2011; 111:191-6. doi:10.1007/978-3-7091-0693-832 PMID: 21725754; PubMed Central PMCID: PMC3563694.
16. Vakili A, Kataoka H, Plesnila N. Role of arginine vasopressin V1 and V2 receptors for brain damage after transient focal cerebral ischemia. J Cereb Blood Flow Metab. 2005; 25(8):1012-9. doi:10.1038/sj.jcbfm.9600097 PMID: 15744246.
17. Hockel K, Scholler K, Trabold R, Nussberger J, Plesnila N. Vasopressin V(1a) receptors mediate posthemorrhagic systemic hypertension thereby determining rebleeding rate and outcome after experimental subarachnoid hemorrhage. Stroke. 2012; 43(1):227-32. doi:10.1161/STROKEAHA.111.626168 PMID: 21998059.
18. Ghali JK. Mechanisms, risks, and new treatment options for hyponatremia. Cardiology. 2008; 111(3):147-57. doi:10.1159/000121596 PMID: 18434717.
19. Bhardwaj A. Neurological impact of vasopressin dysregulation and hyponatremia. Annals of neurology. 2006; 59(2):229-36. doi:10.1002/ana.20788 PMID: 16437573.
20. Villabona C. [Vasopressin receptor antagonists: the vaptans]. Endocrinologiay nutricion: organode la Sociedad Espanolade Endocrinologiay Nutricion. 2010; 57 Suppl 2:41-52. doi:10.1016/S1575-0922(10)70021-8 PMID: 21130961.
21. Laczi F. [Etiology, diagnostics and therapy of hyponatremias]. Orvosi hetilap. 2008; 149(29):1347-54. doi:10.1556/OH.2008.28409 PMID: 18617466.
22. Zeynalov E, Chen CH, Froehner SC, Adams ME, Ottersen OP, Amiry-Moghaddam M, et al. The perivascular pool of aquaporin-4 mediates the effect of osmotherapy in postischemic cerebral edema. Crit Care Med. 2008; 36(9):2634-40. PMID: 18679106; PubMed Central PMCID: PMC2755627.
23. Drugs R.D. Conivaptan: YM 087. Drugs in R&D. 2004; 5(2):94-7. PMID: 15293869.
24. Med Lett Drugs Ther. Conivaptan (Vaprisol) for hyponatremia. The Medical letter on drugs and therapeutics. 2006; 48(1237):51-2. PMID: 16785851.
25. Goldsmith SR, Elkayam U, Haught WH, Barve A, He W. Efficacy and safety of the vasopressin V1A/V2-receptor antagonist conivaptan in acute decompensated heart failure: a dose-ranging pilotstudy. Journal of cardiac failure. 2008; 14(8):641-7. PMID: 18926434.
26. Dosage and Administration of Tolvaptan: FDA; 2013. Available: http://www.accessdata.fda.gov/drugsatfdadocs/label/2013/022275s009lbl.pdf.
27. Ge Y, Ahn D, Stricklett PK, Hughes AK, Yanagisawa M, Verbalis JG, et al. Collecting duct-specific knockout of endothelin-1 alters vasopressin regulation of urine osmolality. American journal of physiology Renal physiology. 2005; 288(5):F912-20. doi:10.1152/ajprenal.00432.2004 PMID: 15632412.
28. Hoggatt AF, Hoggatt J, Honerlaw M, Pelus LM. A spoonful of sugar helps the medicine go down: a novel technique to improve oral gavage in mice. J Am Assoc Lab Anim Sci. 2010; 49(3):329-34. PMID: 20587165; PubMed Central PMCID: PMC2877306.
29. Xing CH, Teranishi Y. V1 receptor activation induced by hemorrhage and sympathoinhibition in the mesentery and hindquarters of spontaneously hypertensive rats. Hiroshima journal of medical sciences. 2005; 54(4):93-9. PMID: 16398053.
30. Taya K, Gulsen S, Okuno K, Prieto R, Marmarou CR, Marmarou A. Modulation of AQP4 expression by the selective V1a receptor antagonist, SR49059, decreases trauma-induced brain edema. Acta neurochirurgica Supplement. 2008; 102:425-9. PMID: 19388360.
31. Marmarou CR, Liang X, Abidi NH, Parveen S, Taya K, Henderson SC, et al. Selective vasopressin-1a receptor antagonist prevents brain edema, reduces astrocytic cell swelling and GFAP, V1aR and AQP4 expression afterfocal traumatic brain injury. Brain Res. 2014; 1581:89-102. doi:10.1016/j.brainres.2014.06.005 PMID:24933327; PubMed Central PMCID: PMC4240002.
32. Hedna VS, Bidari S, Gubernick D, Ansari S, Satriotomo I, Khan AA, et al. Treatment of stroke related refractory brain edema using mixed vasopressin antagonism: a case report and review of the literature. BMC neurology. 2014; 14:213. doi:10.1186/s12883-014-0213-0 PMID: 25403760; PubMed Central PMCID: PMC4237783.
33. Thibonnier M, Coles P, Thibonnier A, Shoham M. The basic and clinical pharmacology of nonpeptide vasopressin receptor antagonists. Annual review of pharmacology and toxicology. 2001; 41:175-202. doi:10.1146/annurev.pharmtox.41.1.175 PMID: 11264455.
34. Chen CH, Xue R, Zhang J, Li X, Mori S, Bhardwaj A. Effect of osmotherapy with hypertonic saline on regional cerebral edema following experimental stroke: a study utilizing magnetic resonance imaging. Neurocritical care. 2007; 7(1):92-100. doi:10.1007/s12028-007-0033-9 PMID: 17657661.
35. Galton C, Deem S, Yanez ND, Souter M, Chesnut R, Dagal A, et al. Open-label randomized trial of the safety and efficacy of a single dose conivaptan to raise serum sodium in patients with traumatic brain injury. Neurocritical care. 2011; 14(3):354-60. doi:10.1007/s12028-011-9525-8 PMID: 21409494.
36. Dhar R, Murphy-Human T. A bolus of conivaptan lowers intracranial pressure in a patient with hyponatremia after traumatic brain injury. Neurocritical care. 2011; 14(1):97-102. doi:10.1007/s12028-010-9366-x PMID: 20440600.
37. O'Donnell ME, Duong V, Suvatne J, Foroutan S, Johnson DM. Arginine vasopressin stimulation of cerebral microvascular endothelial cell Na-K-Cl cotransporter activity is V1 receptor and [Ca] dependent. American journal of physiology Cell physiology. 2005; 289(2):C283-92. doi:10.1152/ajpcell.00001.2005 PMID: 15800057.
38. Bemana I, Nagao S. Treatment of brain edema with a nonpeptide arginine vasopressin V1 receptor antagonist OPC-21268 in rats. Neurosurgery. 1999; 44(1):148-54; discussion 54-5. PMID: 9894975.
39. Velez JC, Dopson SJ, Sanders DS, Delay TA, Arthur JM. Intravenous conivaptan for the treatment of hyponatraemia caused by the syndrome of inappropriate secretion of antidiuretic hormone in hospitalized patients: a single-centre experience. Nephrol Dial Transplant. 2010; 25(5):1524-31. doi:10.1093/ndt/gfp731 PMID: 20064953.
40. Zeynalov E, Jones, S., Seo, JW, Elliott, JP, editor IV Treatment with Arginine-Vasopressin receptor Blocker Vaprisol Reduces Ischemia-Evoked Brain Edema. Critical Care Congress; 2014 December 2014; Crit Care Med, Volume 42, Number 12. Crit Care Med, Volume 42, Number 122014.
41. Krieg SM, Sonanini S, Plesnila N, Trabold R. Effect of small molecule vasopressin V1a and V2 receptor antagonists on brain edema formation and secondary brain damage following traumatic brain injury in mice. J Neurotrauma. 2015; 32(4):221-7. doi:10.1089/neu.2013.3274 PMID: 25111427; PubMed Central PMCID: PMC4321979.